- Motley Fool•11 hours ago
Amgen's top-selling anti-inflammatory drug, Enbrel, may have already hit its high-water mark.
- The Wall Street Journal•2 days ago
French drugmaker Sanofi said 1Q net profit jumped to about $6.2 billion, boosted by the sale of its animal-health business. To revive growth, Sanofi has boosted its research and is seeking to acquire an ...
- Motley Fool•2 days ago
Biosimilars begin to take a small bite out of Johnson & Johnson's top line.
JNJ : Summary for Johnson & Johnson - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||123.27 x 200|
|Ask||123.69 x 400|
|Day's Range||123.13 - 123.90|
|52 Week Range||109.32 - 129.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.75|
|Dividend & Yield||3.20 (2.59%)|
|1y Target Est||N/A|